RxDoctor Payments Data

Salim Shammo, MD

Cardiovascular Disease · Oak Creek, WINPI 1295791937

Payments from drug & device makers

$1,153in general payments, 2019–2025

Across 45 payments — averaging $25.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$266
  • Novartis$233
  • Johnson & Johnson$148
  • Shockwave Medical, Inc$111
  • Kestra Medical Technology Services, Inc.$111
  • E.r. Squibb & Sons, L.L.C.$102
  • plus $182 from 7 others

What the payments were for

  • Food & beverage$1,13598%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,153 in reported general payments places this provider in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$147,745
Medicare patients
877
Services billed
3,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban562$570,649
XareltoRivaroxaban110$127,728
FarxigaDapagliflozin Propanediol69$94,524
Repatha SureclickEvolocumab84$80,713
EntrestoSacubitril/Valsartan39$67,000
JardianceEmpagliflozin29$35,187
Praluent PenAlirocumab23$20,208
Ranolazine ErRanolazine116$12,231
Metoprolol Succinate629$7,628
Ezetimibe256$6,040
Atorvastatin Calcium651$5,656
ClopidogrelClopidogrel Bisulfate463$5,590
Dofetilide61$4,528
Losartan Potassium365$3,859
Rosuvastatin Calcium306$3,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$148$127,728110 claims
AstraZenecaFarxiga$52$94,52469 claims
NovartisEntresto$233$67,00039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Oak Creek

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →